Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.
paper
Cited
Public
Unavailable
- Authors
- Nakajima, Takero; Tanaka, Naoki; Kanbe, Hiroki; Hara, Atsushi; Kamijo, Yuji; Zhang, Xiaowei; Gonzalez, Frank J; Aoyama, Toshifumi
- Year
- 2009
- Journal
- Molecular pharmacology
- PMID
- 19124612
- DOI
- 10.1124/mol.108.052928
- PMCID
- PMC2684924
The triglyceride-lowering effect of bezafibrate in humans has been attributed to peroxisome proliferator-activated receptor (PPAR) alpha activation based on results from rodent studies. However, the bezafibrate dosages used in conventional rodent experiments are typically higher than those in clinical use (> or =50 versus < or =10 mg/kg/day), and thus it remains unclear whether such data can be translated to humans. Furthermore, because bezafibrate is a pan-PPAR activator, the actual contribution of PPARalpha to its triglyceride-lowering properties remains undetermined. To address these issues, bezafibrate at clinically relevant doses (10 mg/kg/day; low) was administered to wild-type and Ppara-null mice, and its effects were compared with those from conventionally used doses (100 mg/kg/day; high). Pharmacokinetic analyses showed that maximum plasma concentration and area under the concentration-time curve in bezafibrate-treated mice were similar to those in humans at low doses, but not at high doses. Low-dose bezafibrate decreased serum/liver triglycerides in a PPARalpha-independent manner by attenuation of hepatic lipogenesis and triglyceride secretion. It is noteworthy that instead of PPAR activation, down-regulation of sterol regulatory element-binding protein (SREBP)-1c was observed in mice undergoing low-dose treatment. High-dose bezafibrate decreased serum/liver triglycerides by enhancement of hepatic fatty acid uptake and beta-oxidation via PPARalpha activation, as expected. In conclusion, clinically relevant doses of bezafibrate exert a triglyceride-lowering effect by suppression of the SREBP-1c-regulated pathway in mice and not by PPARalpha activation. Our results may provide novel information about the pharmacological mechanism of bezafibrate action and new insights into the treatment of disorders involving SREBP-1c.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | 2015 | 25516156 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Proximal Tubule-Specific Genetic Deficiency of PPARΞ± Worsens Systemic Lipid and Glucose Metabolism During Fasting. | Aomura D et al. | β | 2026 | β |
| Impact of natural compounds on peroxisome proliferator-activated receptor: Molecular effects and its importance as a novel therapeutic target for neurological disorders. | Zhu Z et al. | β | 2025 | β |
| Bezafibrate protects blood-brain barrier (BBB) integrity against traumatic brain injury mediated by AMPK. | Yang X et al. | β | 2024 | β |
| Circulating miRNAs associated with nonalcoholic fatty liver disease. | Atic AI et al. | β | 2023 | β |
| Mitochondrial dysfunction, oxidative stress, ER stress and mitochondria-ER crosstalk alterations in a chemical rat model of Huntington's disease: Potential benefits of bezafibrate. | Brondani M et al. | β | 2023 | β |
| Synthesis of microwave-assisted carboxamides in Triton WR-1339-induced hyperlipidemic rats: possible hypolipidemic heterocyclic compounds. | Al-Jammal B et al. | β | 2023 | β |
| Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor Ξ± Modulator (SPPARMΞ±), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARΞ± in Mice. | Zhang Z et al. | β | 2022 | β |
| HRAS germline mutations impair LKB1/AMPK signaling and mitochondrial homeostasis in Costello syndrome models. | Dard L et al. | β | 2022 | β |
| Is there a role of lipid-lowering therapies in the management of fatty liver disease? | Tzanaki I et al. | β | 2022 | β |
| Pemafibrate Protects against Fatty Acid-Induced Nephropathy by Maintaining Renal Fatty Acid Metabolism. | Aomura D et al. | β | 2021 | β |
| Clinical trials in mitochondrial disorders, an update. | Almannai M et al. | β | 2020 | β |
| Effects of dietary phytol on tissue accumulation of phytanic acid and pristanic acid and on the tissue lipid profiles in mice. | Nakanishi T et al. | β | 2020 | β |
| IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate. | Takano K et al. | β | 2020 | β |
| Bezafibrate Prevents Glycine-Induced Increase of Antioxidant Enzyme Activities in Rat Striatum. | Parmeggiani B et al. | β | 2019 | β |
| Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. | Manka P et al. | β | 2019 | β |
| MicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease. | Yu J et al. | β | 2019 | β |
| Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases. | Khuchua Z et al. | β | 2018 | β |
| Synthesis and in Vivo Lipid-Lowering Activity of Novel Imidazoles-5-carboxamide Derivatives in Triton-WR-1339-Induced Hyperlipidemic Wistar Rats. | Jasim SH et al. | β | 2018 | β |
| The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice. | Schafer C et al. | β | 2018 | β |
| Bezafibrate prevents mitochondrial dysfunction, antioxidant system disturbance, glial reactivity and neuronal damage induced by sulfite administration in striatum of rats: Implications for a possible therapeutic strategy for sulfite oxidase deficiency. | Grings M et al. | β | 2017 | β |
| Peroxisome Proliferator-Activated Receptors Associated with Nonalcoholic Fatty Liver Disease. | Wang N et al. | β | 2017 | β |
| Targeting nuclear receptors for the treatment of fatty liver disease. | Tanaka N et al. | β | 2017 | β |
| The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. | Huang Y et al. | β | 2017 | β |
| Age-dependent PPARΞ± activation induces hepatic sulfatide accumulation in transgenic mice carrying the hepatitis C virus core gene. | Tian Y et al. | β | 2016 | β |
| Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis. | Zhang Y et al. | β | 2015 | β |
| Effect of miR-34a in regulating steatosis by targeting PPARΞ± expression in nonalcoholic fatty liver disease. | Ding J et al. | β | 2015 | β |
| Peroxisome proliferator-activated receptors Ξ± and Ξ³ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | β | 2015 | β |
| The dipeptide H-Trp-Arg-OH (WR) Is a PPARΞ± agonist and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells. | Jia Y et al. | β | 2015 | β |
| Ursolic acid improves lipid and glucose metabolism in high-fat-fed C57BL/6J mice by activating peroxisome proliferator-activated receptor alpha and hepatic autophagy. | Jia Y et al. | β | 2015 | β |
| Medium-chain triglyceride supplementation under a low-carbohydrate formula is a promising therapy for adult-onset type II citrullinemia. | Hayasaka K et al. | β | 2014 | β |
| Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster. | Chen W et al. | β | 2014 | β |
| Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models. | Komen JC et al. | β | 2014 | β |
| Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come. | Ghonem NS et al. | β | 2013 | β |
| Flavonol glycosides with lipid accumulation inhibitory activity and simultaneous quantitative analysis of 15 polyphenols and caffeine in the flower buds of Camellia sinensis from different regions by LCMS. | Morikawa T et al. | β | 2013 | β |
| High glucose potentiates L-FABP mediated fibrate induction of PPARΞ± in mouse hepatocytes. | Petrescu AD et al. | β | 2013 | β |
| Peroxisome proliferator-activated receptor Ξ± mediates enhancement of gene expression of cerebroside sulfotransferase in several murine organs. | Nakajima T et al. | β | 2013 | β |
| Sterol regulatory element-binding protein-1c mediates increase of postprandial stearic acid, a potential target for improving insulin resistance, in hyperlipidemia. | Chu X et al. | β | 2013 | β |
| Stimulation of rat liver branched-chain alpha-keto acid dehydrogenase activity by low doses of bezafibrate. | Knapik-Czajka M | β | 2013 | β |
| The pharmacological effects of novel 5-fluoro-N-(9,10-dihydro-9,10-dioxoanthracen-8-yl)-1H-indole-2-carboxamide derivatives on plasma lipid profile of Triton-WR-1339-induced Wistar rats. | Shattat G et al. | β | 2013 | β |
| Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. | Moustafa T et al. | β | 2012 | β |
| Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. | Dumont M et al. | β | 2012 | β |
| Consumption of Pueraria flower extract reduces body mass index via a decrease in the visceral fat area in obese humans. | Kamiya T et al. | β | 2012 | β |
| Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. | Yatsuga S et al. | β | 2012 | β |
| Flavangenol (pine bark extract) and its major component procyanidin B1 enhance fatty acid oxidation in fat-loaded models. | Shimada T et al. | β | 2012 | β |
| PPARΞ± is down-regulated following liver transplantation in mice. | Nakagawa K et al. | β | 2012 | β |
| Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats. | Al-Hiari Y et al. | β | 2011 | β |
| Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome. | Sasaki Y et al. | β | 2011 | β |
| Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders. | Djouadi F et al. | β | 2011 | β |
| Down-regulation of SREBP-1c is associated with the development of burned-out NASH. | Nagaya T et al. | β | 2010 | β |
| Effect of bezafibrate on hepatic oxidative stress: comparison between conventional experimental doses and clinically-relevant doses in mice. | Nakajima T et al. | β | 2010 | β |
| Eicosapentaenoic acid improves hepatic steatosis independent of PPARΞ± activation through inhibition of SREBP-1 maturation in mice. | Tanaka N et al. | β | 2010 | β |
| Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. | Haas MJ et al. | β | 2010 | β |
| Triglycerides and gallstone formation. | Smelt AH | β | 2010 | β |
| PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. | Hardwick JP et al. | β | 2009 | β |